Abstract:Background: DNA methylation is involved in numerous biologic events and associates with transcriptional gene silencing, playing an important role in the pathogenesis of endometrial cancer. ESR1/PGR frequently undergoes de novo methylation and loss expression in a wide variety of tumors, including breast, colon, lung, and brain tumors. However, the mechanisms underlying estrogen and progesterone receptors (ER/PR) loss in endometrial cancer have not been studied extensively. The aims of this study were to determine the expression of DNA (cytosine-5)-methyltransferase 3A/3B (DNMT3A/3B) in endometrial cancer to investigate whether the methylation catalyzed by DNMT3A/3B contributes to low ER/PR expression. Methods: The clinicopathologic information and RNA-Seq expression data of DNMT3A/3B of 544 endometrial cancers were derived from The Cancer Genome Atlas (TCGA) uterine cancer cohort in May 2018. RNA-Seq level of DNMT3A/3B was compared between these clinicopathologic factors with t-test or one-way analysis of variance. Results: DNMT3A/3B was overexpressed in endometrioid carcinoma (EEC) and was even higher in non-endometrioid carcinoma (NEEC) (DNMT3A, EEC vs. NEEC: 37.6% vs. 69.9%, t= -7.440, P < 0.001; DNMT3B, EEC vs. NEEC: 42.4% vs. 72.8%, t= -6.897, P < 0.001). In EEC, DNMT3A overexpression was significantly correlated with the hypermethylation and low expression of the ESR1 and PGR (P <0.05). The same trend was observed in the DNMT3B overexpression subgroup. In the ESR1/ PGR low-expression subgroups, as much as 83.1% of ESR1 and 59.5% of PGR were hypermethylated, which was significantly greater than the ESR1/PG R high-expression subgroups (31.3% and 11.9%, respectively). However. the above phenomena were absent in NEEC, while DNMT3A13B overexpression, ESR1/PGR hypermethylation, and low ER/PR expression occurred much more often. In univariate analysis, DNMT3A/3B overexpressions were significantly correlated with worse prognosis. In multivariate analysis, only DNMT3A was an independent predictor of disease-free survival (P < 0.05). Conclusions: DNMT3A13B expression increases progressively from EEC to NEEC and is correlated with poor survival. The mechanisms underlying low ER/PR expression might be distinct in EEC vs. NEEC. In EEC, methylation related to DNMT3A/3B overexpression might play a major role in ER/PR downregulation.

Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas

[Characteristic and Clinical Significance of DNA Methyltransferase 3B Overexpression in Endometrial Carcinoma].

Upregulation of Microrna Mir-141-3p and Its Prospective Targets in Endometrial Carcinoma: a Comprehensive Study.

DNMT3A/3B Overexpression Might Be Correlated with Poor Patient Survival, Hypermethylation and Low Expression of ESR1/PGR in Endometrioid Carcinoma: an Analysis of the Cancer Genome Atlas

Mir-200A/mir-141 and Mir-205 Upregulation Might Be Associated with Hormone Receptor Status and Prognosis in Endometrial Carcinomas.

1069 MicroRNA-143 is a Potential Tumor Suppressor Targeting DNA Methyltransferases 3a in Colorectal Cancer

Mirna–mrna Associated with Survival in Endometrial Cancer

Methylation-associated Silencing of Mir-638 Promotes Endometrial Carcinoma Progression by Targeting MEF2C

MicorRNA-148b inhibits cell proliferation and facilitates cell apoptosis by regulating DNA Methyltransferase 1 in endometrial cancer

Overexpression of Microrna-205 Predicts Lymph Node Metastasis and Indicates an Unfavorable Prognosis in Endometrial Cancer

[Microrna Expression Signature Profile and Its Clinical Significance in Endometrioid Carcinoma].

MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer

MicroRNA-182 Promotes Tumor Cell Growth by Targeting Transcription Elongation Factor A-like 7 in Endometrial Carcinoma

A Double-Negative Feedback Interaction Between MicroRNA-29b and DNMT3A/3B Contributes to Ovarian Cancer Progression

Down-regulation of miR-449a/b in Type Ⅱ Endometrial Carcinoma

Suppressive Effect of Microrna-449A on the NDRG1/PTEN/AKT Axis Regulates Endometrial Cancer Growth and Metastasis

The Correlation Between Microrna490-3P and TGFα in Endometrial Carcinoma Tumorigenesis and Progression.

Development of Potential Prognostic Biomarkers Based on DNA Methylation-Driven Genes for Patients with Endometrial Cancer.

miR-497-5p Decreased Expression Associated with High-Risk Endometrial Cancer

Prognostic Value of MicroRNAs in Esophageal Carcinoma: A Meta-Analysis.

Comprehensive Analysis of DNA Methylation and Transcriptome to Identify PD-1-Negative Prognostic Methylated Signature in Endometrial Carcinoma.